A novel oncogene has been recently found activated in human thyroid carcinomas. This oncogene was named RET/PTC and was shown to be a chimeric gene, product of the fusion of the tyrosinekinase domain or the RET proto-oncogene to the 5'-terminal region of another gene named H4 or D10S170. A paracentric inversion (10) (q 11.2-21) was demonstrated to be responsible for the H4/RET fusion. Thyroid tumors consist of a broad range of lesions ranging from the benign follicular adenomas to the differentiated papillary and follicular carcinomas and to the fatal anaplastic carcinomas. Papillary and follicular carcinomas have different clinical behaviours and are associated with different risk factors, thus they are probably related to different genetic events. In fact the activation of RET is restricted to the papillary subtype. Here we show the activation of the RET oncogene in 2 out of 10 new cases of papillary thyroid carcinomas.
- Gene rearrangement
- Thyroid carcinoma
ASJC Scopus subject areas
- Environmental Science(all)
- Earth and Planetary Sciences(all)
- Agricultural and Biological Sciences(all)